What is Denator?
Denator AB, headquartered in Gothenburg, Sweden, operates at the critical intersection of biotechnology and analytical science. The company's core innovation lies in its proprietary heat-inactivation technology, designed to stabilize biological tissues and fluids immediately upon sampling. This stabilization process is crucial for preventing sample degradation, thereby ensuring the integrity and quality of data generated by downstream analytical techniques. By standardizing sample treatment, Denator empowers researchers and scientists to achieve more reliable and accurate results, advancing fields that rely on precise biological measurements.
How much funding has Denator raised?
Denator has raised a total of $36M across 6 funding rounds:
Series A
$664K
Series B
$2.2M
Series C
$2.2M
Series D
$1.7M
Series E
$3.9M
Series F
$25.5M
Series A (2006): $664K, investors not publicly disclosed
Series B (2007): $2.2M led by Servisen Investment Management
Series C (2009): $2.2M supported by Servisen Investment Management
Series D (2011): $1.7M featuring SGP Group
Series E (2012): $3.9M backed by Almi Invest
Series F (2012): $25.5M with participation from Almi Foretags
Key Investors in Denator
Almi Foretags
Almi Foretags is a state-owned entity providing financing and business development support to Swedish SMEs, focusing on sustainable growth and future preparedness through loans and venture capital.
Servisen Investment Management
Servisen Investment Management operates in the investment banking sector, likely providing strategic financial guidance and capital to companies within its operational scope.
SGP Group
SGP Group specializes in facilitating market entry for businesses, particularly between South America and China, acting as a connector for suppliers, market research, and sales without requiring a local office.
What's next for Denator?
With a history of consistent capital raises, including significant enterprise-level backing, Denator appears poised for continued expansion and technological advancement. The recent major strategic investment suggests a phase of scaling operations, further product development, or market penetration. The company's focus on enhancing data quality through sample stabilization positions it to capitalize on the growing demand for robust and reproducible scientific research across the pharmaceutical, diagnostic, and academic sectors. Future growth will likely involve broadening the application of its heat-inactivation technology and forging strategic partnerships to integrate its solutions into diverse analytical workflows.
See full Denator company page
